Investigating a genetic factor linked to aggressive prostate cancer in African American men
The ODC A allele as a driver and therapeutic target of aggressive prostate cancer in African American men
This study is looking at how a certain gene variation might affect the risk of aggressive prostate cancer in African American men, and it’s also testing a drug that could help treat those who have this genetic trait.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10560516 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific genetic variation, the ODC A allele, influences the development of aggressive prostate cancer in African American men. By analyzing DNA samples from both African American and European American prostate cancer patients, the study aims to determine the role of this genetic factor in cancer progression. Additionally, it explores the potential of a drug called DFMO, which inhibits the enzyme associated with this allele, as a treatment option for those affected. The goal is to identify patients who may benefit from targeted therapies based on their genetic makeup.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American men diagnosed with prostate cancer who carry the ODC A allele.
Not a fit: Patients who do not have prostate cancer or those who are not African American may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment strategies for African American men with prostate cancer, improving outcomes and survival rates.
How similar studies have performed: Previous research has indicated that targeting genetic variations in cancer can lead to successful treatment outcomes, suggesting this approach has potential.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Park, Jong Y. — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Park, Jong Y.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.